AC
IMDX

AXQ Capital’s Insight Molecular Diagnostics IMDX Stock Holding History

AXQ Capital’s Portfolio IMDX Stock Details IMDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$79.1K Buy
+13,407
New +$66.2K 0.01% 872

Other funds holding IMDX

FOR
Family Office Research Bethesda, Maryland $267M AUM 27.99% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return
EWA
EverSource Wealth Advisors Birmingham, Alabama $2.97B AUM 28.72% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return
CIAM
Caitong International Asset Management Hong Kong $729M AUM 1,176.98% 1-Year Est. Return

AXQ Capital's IMDX Position: Q2 2026 in Review

AXQ Capital opened a new position in Insight Molecular Diagnostics (IMDX) in Q2 2026: 13,407 shares worth $79.1K. The stake represents 0.01% of the portfolio and ranks #872 among its holdings.

17 funds tracked by Wall St. Rank hold IMDX as of Q2 2026.

  • AXQ Capital held 13,407 shares of Insight Molecular Diagnostics worth $79.1K as of Q2 2026.
  • Insight Molecular Diagnostics was a new AXQ Capital position in Q2 2026.
  • Insight Molecular Diagnostics made up 0.01% of AXQ Capital's portfolio in Q2 2026, its #872 holding.
  • 17 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q2 2026.

Based on AXQ Capital's 13F filing for Q2 2026, filed 6 Aug 2026.